Regenerative Medical Technology (RMTG) Operating Margin (2018 - 2026)
Regenerative Medical Technology (RMTG) posted Operating Margin of 14.07% for Q2 2026, up 61.6% on a QoQ basis from 8.71% in Q1 2026, and up 3950.0% year-over-year from 0.35% in Q2 2025.
Powered by 
Analysis
Regenerative Medical Technology (RMTG) Operating Margin (2018 - 2026) Analysis & Trends
Regenerative Medical Technology has reported Operating Margin for 9 years, with the latest figure at 14.07% in Q2 2026.
- On a quarterly basis, Operating Margin rose 3950.0% year-over-year to 14.07% in Q2 2026; TTM through Jun 2026 was 0.46%, a 542.0% decrease from a year earlier, with the FY2025 full-year figure at 17.0%, down 1898.0% from the prior year.
- Operating Margin was 14.07% for Q2 2026 at Regenerative Medical Technology, up from 8.71% in the prior quarter.
- The five-year high for Operating Margin was 25.19% in Q4 2024, with the low at 433.93% in Q4 2022.
- Average Operating Margin over 5 years is 55.96%, with a median of 20.72% recorded in 2023.
- The largest YoY upside for Operating Margin was 541852 bps in 2022 against a maximum downside of 23737 bps in 2022.
- Over 5 years, Operating Margin stood at 433.93% in 2022, then surged by 95 bps to 21.95% in 2023, then jumped by 215 bps to 25.19% in 2024, then tumbled by 177 bps to 19.48% in 2025, then surged by 172 bps to 14.07% in 2026.
- The last three Operating Margin figures came in at 14.07% (Q2 2026), 8.71% (Q1 2026), and 19.48% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.21 Bn | 9.37 Bn | 112.79 Mn | 49.00% |
| 2 | CRISPR Therapeutics AG | 5.03 Bn | 5.03 Bn | - | -1,151.84% |
| 3 | Iovance Biotherapeutics | 3.66 Bn | 3.36 Bn | 55.72 Mn | -52.26% |
| 4 | Legend Biotech | 3.54 Bn | 2.57 Bn | 251.50 Mn | 14.89% |
| 5 | uniQure | 2.99 Bn | 2.99 Bn | 5.49 Mn | -893.73% |
| 6 | Beam Therapeutics | 2.52 Bn | 2.52 Bn | - | -25,827.14% |
| 7 | Precigen | 2.38 Bn | 2.38 Bn | 52.17 Mn | 41.18% |
| 8 | Sarepta Therapeutics | 2.15 Bn | 1.35 Bn | 251.87 Mn | 3.31% |
| 9 | Vericel | 1.93 Bn | 1.77 Bn | 56.40 Mn | 0.56% |
| 10 | Regenerative Medical Technology | 1.12 Mn | -199,206.02 | 2.58 Mn | 14.07% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 14.07% |
| Mar 31, 2026 | 8.71% |
| Dec 31, 2025 | -19.48% |
| Sep 30, 2025 | -37.76% |
| Jun 30, 2025 | -25.43% |
| Mar 31, 2025 | 9.89% |
| Dec 31, 2024 | 25.19% |
| Sep 30, 2024 | 1.99% |
| Jun 30, 2024 | -26.97% |
| Mar 31, 2024 | -12.86% |
| Dec 31, 2023 | -21.95% |
| Sep 30, 2023 | -11.60% |
| Jun 30, 2023 | -119.23% |
| Mar 31, 2023 | -9.44% |
| Dec 31, 2022 | -433.93% |
| Sep 30, 2022 | -43.97% |
| Jun 30, 2022 | -122.89% |
| Mar 31, 2022 | -181.55% |
| Dec 31, 2021 | -196.56% |
| Sep 30, 2021 | -5,462.49% |